372 results about "Ovary" patented technology

The invention provides a traditional Chinese medicine composition for treating ovarian reserve function decline. The traditional Chinese medicine composition is prepared from the following medicines in parts by mass: 9-30 parts of radix astragali preparata, 6-20 parts of roasted rhizoma atractylodis macrocephalae, 10-15 parts of poria cocos, 2-10 parts of radix glycyrrhizae preparata, 6-20 parts of semen cuscutae, 9-20 parts of radix dipsaci (dipsacus root), 6-12 parts of herba lycopi and 6-15 parts of lily. Experimental results show that the traditional Chinese medicine composition is suitable for improving the ovarian function of a patient suffering from spleen-kidney deficiency type ovarian reserve function decline.

The invention belongs to the technical field of biology, and particularly relates to a receptor peptidomimetic capable of improving the breeding efficiency of butter crabs and application of the receptor peptidomimetic. The optimal binding conformation is screened according to the sequence prediction binding conformation of the vitellogen and the receptor of the vitellogen, the hotspot residues are screened according to the optimal binding conformation, and the binding energy change before and after mutation of the hotspot residues is calculated to determine the receptor peptidomimetic sequence. The receptor peptidomimetic can obviously slow down the development speed of the ovary of the blue crab and effectively induce the formation of the butter crab by utilizing the specificity of specific recognition of the vitellogenin of the blue crab and the receptor, so that the butter crab product can be produced in a planned manner.

The invention discloses a health-care food for delaying ovarian aging, which belongs to the technical field of health-care foods and comprises a composition for improving the levels of anti-mullerian test tube hormone and superoxide dismutase and functional auxiliary materials, the composition for improving the anti-muller test tube hormone and superoxide dismutase level is prepared from the following components in parts by weight: 2 to 5 parts of pyrroloquinoline quinone PQQ, 30 to 80 parts of cranberry powder and 40 to 100 parts of an isoflavone extract, and the content of the pyrroloquinoline quinone PQQ is 2 to 5 parts, the content of the cranberry powder is 30 to 80 parts, and the content of the isoflavone extract is 40 to 100 parts. The pyrroloquinoline quinone PQQ, the cranberry powder and the isoflavone extract in a specific formula have the effect of synergistically improving the levels of anti-muller test tube hormone and superoxide dismutase, and the health food prepared from the pyrroloquinoline quinone PQQ, the cranberry powder and the isoflavone extract can improve sleep, improve urinary tract infection of middle-aged women, delay ovarian aging and the like.

The invention discloses a traditional Chinese medicine composition for treating or improving hypoovarian reserve function and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition comprises the following components in parts by weight: angelica sinensis, parched white paeony root, parasitic loranthus, dodder, roasted rhizoma atractylodis macrocephalae, ligusticum wallichii, herba lycopi, albizia flower and honey-fried licorice root. And after ovulation, morinda officinalis and glossy privet fruit are added. The formula provided by the invention complies with the natural law of human bodies, and according to the growth of qi and blood, yin and yang, nourishing blood, activating blood and tonifying kidney, yin and yang are tonified without stagnation, and blood stasis is removed without hurting healthy qi; meanwhile, the traditional Chinese medicine is used for strengthening the root of acquired days, quieting the main internal organs, combining dynamic and static, regulating qi-blood yin-yang balance and taking the balance as a period. The invention further provides application of the composition or the traditional Chinese medicine extract or the traditional Chinese medicine preparation in preparation of a medicine for treating or improving ovarian reserve hypofunction.

The invention provides a polypeptide with an ovary maturation promoting effect and application of the polypeptide in parturition induction of pomfret. The amino acid sequence of the polypeptide is SEQ ID NO: 1. The polypeptide provided by the invention is derived from the GnRH2 gene of the pomfret, and in-vivo experiments prove that the polypeptide can efficiently stimulate the pituitary of the pomfret to secrete gonadotropin, so that the spawning induction time is remarkably shortened, and the spawning rate and the relative spawning amount of parent fish are increased. The polypeptide is strong in species specificity and good in physiological compatibility, does not generate an antibody, avoids side effects of traditional heterologous hormones, is safe and effective, and has a huge potential of being developed into a special spawning induction agent for the pomfret.

Provided are pharmaceutical formulations comprising a recombinant acid α-glucosidase, wherein the recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an increased content of N-glycan units bearing one or two mannose-6-phosphate residues when compared to a content of N-glycan units bearing one or two mannose-6-phosphate residues of alglucosidase alfa; at least one buffer selected from the group consisting of a citrate, a phosphate and combinations thereof; and at least one excipient selected from the group consisting of mannitol, polysorbate 80, and combinations thereof, wherein the formulation has a pH of from about 5.0 to about 7.0. Also provided are methods of treating Pompe disease using these pharmaceutical formulations.

The invention discloses a culture device for improving polycystic ovarian syndrome lactobacillus reuteri, and belongs to the technical field of lactobacillus reuteri culture.The culture device comprises a working frame, the inner side of the working frame is fixedly connected with a feeding mechanism used for conveying, one side of the feeding mechanism is fixedly connected with a culture mechanism, and the other side of the feeding mechanism is fixedly connected with a conveying mechanism; a liquid feeding mechanism is fixedly connected to the rear side of the feeding mechanism, a supporting mechanism is fixedly connected to the position, located between the feeding mechanism and the culture mechanism, of the inner side of the working frame, an auxiliary ladder is fixedly connected to the surface of one side of the working frame, and a protection frame is fixedly connected to the surface of the auxiliary ladder. On the basis of realizing auxiliary culture of lactobacillus reuteri, strain functions and metabolites can be accurately regulated and controlled, and the delivery problem in PCOS treatment can be solved.

The application discloses a construction method and application of an ovary cell line of Quasipaa spinosa. The method comprises the following steps: selecting metamorphosis period larva ovary tissue, disinfecting and obtaining the ovary tissue, and then using collagenase I digestion solution to digest the ovary tissue at 26 DEG C for 1 hour; after the tissue block adheres to the wall, using a low-osmotic-pressure complete culture medium to carry out primary culture at 25-27 DEG C, wherein the culture medium is 60% diluted DMEM / F12 culture medium containing 10%-15% fetal bovine serum; when the cell confluence degree is higher than 70%, using trypsin-EDTA to digest the cells for 1-2 minutes to subculture, and the subculture culture medium contains 30% cell conditional culture medium; and finally, the cells are cryopreserved through programmed cooling. The ovary epithelial cell line of Quasipaa spinosa is successfully established for the first time, the survival rate of the cells after recovery is high, and the karyotype is stable. The constructed cell line can be used for amphibian reproductive biology research, compound screening and in-vitro conservation of germplasm resources.

The invention discloses application of an ACSL4 inhibitor in preparation of a medicine for improving quality reduction of an elderly ovum, and belongs to the technical field of biological medicines. The invention provides an application of targeting long-chain fatty acid acyl-coenzyme A synthetase 4 (ACSL4) in intervention of low oocyte quality and related fertility decline caused by aging. The ACSL4 inhibitor can be used for preparing drugs for improving ovarian functions and improving oocyte quality. In-vivo and in-vitro experiments prove that by inhibiting the ACSL4, the aging process of the elderly ovary can be effectively relieved, the expression of aging-related proteins p16 and p21 can be reduced, the mitochondrial function of the oocyte can be improved, and spindle assembly abnormality and chromosome arrangement defects can be rescued, so that the maturation rate and the development potential of the oocyte can be remarkably improved.

The invention relates to health-preserving conditioning tea and a preparation method thereof, and belongs to the technical field of tea drinks, and the health-preserving conditioning tea comprises a paederia scandens extract, a radix fici simplicissimae extract, a Chinese yam-eclipta alba distilled liquid medicine and an angelica sinensis extract. The prepared health-preserving conditioning tea can help human body aging. Meanwhile, ovarian senescence can be delayed, and the ovarian health state can be improved.

The invention discloses a timed insemination method for improving the pregnancy rate and the lambing rate of sheep, and belongs to the technical field of livestock breeding. In order to solve the problem that the pregnancy rate of existing sheep is unstable during regular insemination, the method comprises the steps that a progesterone sponge suppository is embedded in the vagina of a healthy and reproductive ewe on the 0th day, and meanwhile 25 g of luteinizing hormone is injected in an intramuscular mode to release hormone A3; removing the thrombus on the 12th day, and performing intramuscular injection of 400IU of pregnant mare serum gonadotropin at the same time; and after the suppository is removed, insemination is carried out on the cervix orifice of the ewe with ram semen diluted at the ratio of 1: (5-8) in 52h and 64h respectively. According to the method, ovarian activities of the ewes are regulated and controlled, the estrus synchronism and the ovulation rate are improved, tests show that the pregnancy rate reaches 81.6%, the lambing rate is 1.14, compared with a conventional method, the pregnancy rate and the lambing rate of the sheep are remarkably improved, and development of the sheep industry is promoted.

Treatment of hirsutism, polycystic ovary syndrome, and other related conditions. This invention relates to a novel treatment for hirsutism, wherein a combination of dinogest and ethinylestradiol is administered to the subject in need.

The invention provides a novel application of a raspberry extract. It is found through tests that any one of isoquercitrin, ellagic acid, vanillic acid, oleanolic acid, kaempferol-3-O-rutinoside, kaempferol-3-O-sophoroside, tiliroside, tormentic acid and raspberry extract can remarkably improve the activity of the human ovarian granular cells or remarkably improve the oxidative stress level, and the activity of the human ovarian granular cells can be remarkably improved. According to the present invention, the ovarian function can be effectively protected by the eight components, the ovarian function can be effectively protected by the eight components, or the mitochondrial membrane potential level can be significantly regulated and controlled, or the estrogen level in the microenvironment can be effectively maintained, such that the ovarian function can be effectively protected by the eight components, and the raspberry extract containing the eight components. The invention provides a new choice for ovarian function protection products, and also provides a new application for the substances.

The invention relates to a traditional Chinese medicine composition for treating or / and preventing hypoovarian reserve function as well as a preparation method and application thereof, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 0.8-1.2 parts of mulberries, 0.8-1.2 parts of Chinese wolfberry fruits, 0.8-1.2 parts of lily bulbs and 1.2-1.8 parts of Chinese yams stir-fried with bran. The invention further provides a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition mainly tonifies kidney and replenishes essence, nourishes blood and yin, gives consideration to lung, spleen and liver, clears away heart fire and tranquillizes the mind, is homologous in medicine and food, few in medicine flavor and good in medicine effect, and is especially short in treatment course when being taken during ovulation promotion. Clinical curative effect observation and animal experiments both prove that under the specific dosage ratio, the synergistic interaction effect can be achieved.

The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer-implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Fibroblast Growth Factor-Binding Protein 1 (FGFBP1) in a sample of the subject.

The invention discloses a preparation method of cryptotanshinone-loaded PDA (Polydopamine) nano drug-loaded particles. The technical scheme adopted by the invention is as follows: the cryptotanshinone is loaded on PDA (Polydopamine) nano particles. Photo-thermal therapy and pharmaceutical chemotherapy are integrated into designed nano-delivery to impart a targeted synergistic effect thereto. In addition, the PDA nanoparticles show photoacoustic imaging capability, and aggregation of the nanoparticles at the ovary part can be monitored in real time. The cryptotanshinone is loaded by utilizing aperture adsorption of PDA and pi-pi conjugation and hydrophobic interaction with the cryptotanshinone, so that a drug delivery system is constructed, the biological solubility and the utilization rate of the cryptotanshinone are improved, a slow release effect is achieved, the application of the cryptotanshinone is widened, and the purpose of treating the polycystic ovarian syndrome is achieved.

The present application relates to the field of biological medicine and modernization of traditional Chinese medicine, and particularly relates to a therapeutic target, an inhibitor and a traditional Chinese medicine composition for treating ovarian hypofunction caused by oxidative stress and application thereof. The present application first determines SRC tyrosine kinase as a key drug target for preventing and treating the disease. The application of the SRC tyrosine kinase inhibitor (such as secaitinib) in preparing related drugs is provided, which can alleviate the damage of ovarian granulosa cells by inhibiting the SRC activity, down-regulating the expression of antioxidant enzyme related genes and reducing the level of active oxygen. Meanwhile, the present application provides a traditional Chinese medicine composition composed of mulberry, kudzu root, tuckahoe and medlar. The composition can improve the hormone level, enhance the antioxidant capacity, improve the ovarian function and fertility by inhibiting the SRC tyrosine kinase activity and the SRC-RAF1-MEK-ERK signal pathway. The present application provides a new solution for the targeted treatment of ovarian hypofunction and the modernization of traditional Chinese medicine.

The application belongs to the technical field of biomedicine, and particularly relates to a miRNA marker for diagnosing polycystic ovary syndrome and application thereof. The miRNA marker comprises one or a combination of hsa-miR-185-5p and hsa-miR-4433b-3p. The application first uses a plurality of extracellular vesicle (EVs) miRNAs such as hsa-miR-185-5p for diagnosing polycystic ovary syndrome patients, and it is found through verification in real clinical samples collected in the application that the plurality of extracellular vesicle (EVs) miRNAs such as hsa-miR-185-5p have good diagnostic efficiency for diagnosing polycystic ovary syndrome, and have high accuracy, sensitivity and specificity, and can be used for effective diagnosis of polycystic ovary syndrome. The application provides a brand-new thought and strategy for research and development of polycystic ovary syndrome related diagnostic products, and has a wide application prospect and important transformation significance in the technical field of polycystic ovary syndrome diagnosis.

The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that binds specifically to human CD28, and a second antigen-binding domain that binds specifically to human MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention can inhibit the growth of tumors expressing MUC16, such as ovarian tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is convenient and / or therapeutically beneficial.

The present invention relates to a medium composition for in vitro fertilization and / or in vitro culture comprising a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof, and a method using same. The compound or composition suppresses reactive oxygen species and lipid peroxidation in ovarian granulosa cells to preventing cytotoxicity and mitochondrial dysfunction caused by apoptosis and ferroptosis, leading to an improvement in the quality of aged oocytes, and to increase the developmental rate and blastocyst formation rate of pre-implantation embryos, thereby improving the efficiency of in vitro fertilization. In addition, treatment with the medium composition during the vitrification process of in vitro–fertilized embryos improves re-expansion and survival rates, thereby reducing structural and metabolic damage. Accordingly, the present invention can be advantageously applied to an assisted reproductive technology for treating infertility and subfertility, and in vitro fertilization and / or in vitro culture for improving the propagation efficiency of livestock.

1. The name of the design product: medical detection chip. 2. The use of the design product: the design product is used for non-invasive early screening of polycystic ovary syndrome. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: design 1 perspective view 1. 5. Design 1 is designated as the basic design.

The present invention is related to a method of determining suitability of at least one Chinese Hamster Ovary (CHO) test cell line for optimal heterologous protein production, the method comprising:(a) determining a test methylation profile from genomic material obtained from the CHO test cell line; and(b) comparing the test methylation profile obtained from (a) with a reference methylation profile, wherein the reference methylation profile comprises the methylation status of more than one CpG site from at least one CHO reference cell line that displays at least one phenotype of interest for optimal heterologous protein production,wherein a significant similarity in the test methylation profile of (a) compared to the reference methylation profile, is indicative of the CHO test cell line being suitable for optimal heterologous protein production and wherein the test methylation profile and reference methylation profile are from CpG sites from the CHO cell genome and are determined using DNA methylation-bead-based array.

The invention discloses a small molecule RNA (Ribonucleic Acid) and application thereof in preventing and treating diaphorina citri. The inventor finds that the miRNA of the diaphorina citri, namely the RNA miR-7, has a nucleotide sequence of 5 '-UGAACACAGCUGGGUGGUAUCUC-3', and is highly expressed in an ovary and a head of the diaphorina citri. By feeding miR-7 agonist, the oviposition amount of diaphorina citri is remarkably reduced, ovarian development is abnormal, the titer of Candidatus Liberibacter asiaticum in the ovarian is remarkably reduced, and the miR-7 agonist has a good application prospect for preventing and treating diaphorina citri and then preventing and treating the Candidatus Liberibacter

The present invention relates to a double-lumen oocyte aspiration needle and use thereof in the collection of oocytes from the ovaries of animals undergoing assisted reproduction procedures.

The application relates to an ovarian reserve function index processing data evaluation method and system, which comprises the following steps: obtaining a clinical detection data set containing the age of a female and the measured value of serum anti-Mullerian hormone, screening, and obtaining an effective sample set; grouping the effective sample set and calculating the mean, standard deviation and sample number thereof to obtain an original statistical distribution benchmark; positioning a core dense area of the original statistical distribution benchmark to obtain a core dense data intercept segment; converting the core dense data intercept segment into a standardized core data set, constructing an age-AMH linear regression model based on the standardized core data set; calculating the same-age theoretical AMH value through the linear regression model to obtain a JCA index; and performing multi-level risk quantitative evaluation on the JCA index to obtain a quantitative evaluation result. The embodiment solves the technical problems of age incomparability, poor distinguishability and lack of unified quantitative standard in the prior art.

The invention discloses application of expression of a targeted silence TdSb-sbd gene in increasing the egg laying amount of female trichogramma dendrolimus, and belongs to the technical field of biological prevention and control. The invention discovers that the SPS protein (coding gene TdSb-sbd) of trichogramma dendrolimus can interact with the juvenile hormone degradation key enzyme JHEH1 protein. After the TdSb-sbd gene is silent in a targeted manner, the expression level of the gene can be reduced, and the expression of an interaction protein coding gene Tdjheh1 of the gene is reduced, so that the degradation pathway of juvenile hormone (JH) is inhibited, and the titer of juvenile hormone in trichogramma is improved. The high juvenile hormone level can promote ovarian development and ovum generation of trichogramma, and finally the egg laying amount of female bees is remarkably increased. The trichogramma reproductive capacity is directly regulated and controlled through a molecular biology means, and a new technical scheme is provided for improving the trichogramma dendrolimus reproductive capacity and the field pest control efficiency on a large scale.

The current invention is in the field of molecular biology / pharmacology and provides novel 3-oxabicyclo[3.3.1]nonene compounds and derivatives that modulate the effects of the classical estrogen receptors alpha and beta (ERalpha and ERbeta) with little to no biological or physiological effects on the G protein-coupled estrogen receptor GPER (also known as GPR30). These compounds may function as agonists and / or antagonists of one or more of the disclosed classical estrogen receptors. Diseases that are mediated through one or more of these receptors include cancer (including but not limited to breast (particularly endocrine or anti-hormone resistant, and for the prevention / reduction of endocrine or anti-hormone resistance), reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometritis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disorders (such as Parkinson's disease and Alzheimer's disease), as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine, among numerous others as described herein. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.

The application relates to the technical field of animal models, in particular to a modeling method and an evaluation method of an animal menstrual dysmenorrhea model and application, wherein the animal with removed ovaries is injected with estrogen, progesterone and oxytocin, the pharmacological injection of progesterone can reduce the harm and mortality rate of the animal caused by the implantation and removal of a progesterone release body in the prior art, the surgical stress of the animal is reduced, the injection time of the progesterone in the application is 7-9 days, and the animal menstrual dysmenorrhea model is obtained after the progesterone is withdrawn for 16 hours; after evaluation by the evaluation method, compared with the non-menstrual process of the dysmenorrhea model in the prior art, the animal menstrual dysmenorrhea model can better simulate the pathophysiological process of human dysmenorrhea, promote the development of clinical treatment, and effectively help patients to relieve pain.

The application relates to the technical field of animal model construction, in particular to a construction method and application of a spleen-kidney yang deficiency syndrome ovarian reserve function decline animal model. The construction method comprises the following steps: a model group animal is subjected to modeling by adopting the method of senna leaf water decoction gavage and hydrocortisone and cyclophosphamide injection, and a spleen-kidney yang deficiency syndrome ovarian reserve function decline animal model is obtained. In the application, the three of senna leaf, hydrocortisone and cyclophosphamide are used in synergy to administer the animal model, and the complex syndrome of the clinical spleen-kidney yang deficiency type DOR is accurately reproduced, and modern scientific basis is provided for the theories of traditional Chinese medicine such as the same treatment for different diseases.

The invention relates to a method for improving PD-1 titer produced by Chinese hamster ovary cells. The method comprises the following steps: inoculating the Chinese hamster ovary cells into an initial culture medium for culturing; after the culture is performed for 48 hours, feeding a fed-batch culture medium every day, and maintaining the glucose concentration in the culture medium to be 1.3-1.7 g / L, the galactose concentration to be 0.6-1.0 g / L and the L-sodium lactate concentration to be 14-16 mM; the culture temperature is reduced, a fed-batch culture medium is fed every day, the glucose concentration in the culture medium is maintained at (2-2.8) g / L, the galactose concentration is maintained at (1.7-2.2) g / L, and cells are harvested. Galactose is introduced to serve as a second carbon source, and control over the culture initial metabolism environment and the carbon source in the culture stage is combined, so that the maximum accumulation amount of lactic acid is obviously reduced, the cell culture period is remarkably prolonged, and the maximum titer of the PD-1 antibody is remarkably improved compared with an existing process.